Please assess the completion status of the following clinical trial:

Trial Title: Sputum-derived Cellular Targets After Xolair (Omalizumab)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Physician diagnosed asthma~* Lung function (one or more of the following documented in the 5 years before enrollment or demonstration during screening) 1. Bronchial hyper responsiveness (BhR) confirmed by ≥ 12% improvement in FEV1 post bronchodilator within the previous 5 years, or 2. Methacholine PC20 \< 16mg/dl within the previous 5 years~* Severity Criteria: Moderate-persistent asthma defined by the American Thoracic Society (ATS)~* Asthma Control: Partly or uncontrolled asthma according to GINA 2012 guidelines (at least three of the following features: daytime symptoms more than 2 times/week, limitation of activities, nocturnal symptoms, need for rescue inhaler \> 2 times/week, FEV1 \<80% predicted)~* Stable use of moderate-high dose inhaled corticosteroids in previous 3 months (definition derived from GINA 2012 guidelines: e.g. fluticasone propionate \>250 mcg/day, budesonide \> 400mcg/day)~* Ability to perform induced sputum maneuvers~* Presence of elevated allergen IgE to any perennial aeroallergen~Exclusion Criteria:~* Pulmonary function: FEV1 ≤ 70% predicted~* Any major chronic illness including but not limited to Chronic Obstructive Pulmonary Disease (COPD), uncontrolled hypertension, coronary artery disease, bronchiectasis, congestive heart failure, stroke, cystic fibrosis, insulin-dependent diabetes mellitus, renal failure, liver disorders, immunodeficiency state, or other condition that would interfere with participation in the study~* Current or \> 10 pack a year pack-year tobacco use~* Any investigational study within previous 1 month~* Inability to perform baseline measurements~* Inability to contact by telephone~* Pregnancy at screening and failure to use double barrier pregnancy protection in woman of childbearing age~* Hypersensitivity reaction to omalizumab in the past~* Exceeds limits of dosing table (IgE \<30 or 700 IU/ml) or body weight of \<30 or \> 150kg~* Systemic corticosteroids within the previous month~* Known malignant neoplasm

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Omalizumab (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).